NYSE:ANTM

Anthem Competitors

$381.88
+2.22 (+0.58 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$378.07
Now: $381.88
$386.78
50-Day Range
$303.19
MA: $350.05
$375.62
52-Week Range
$244.10
Now: $381.88
$386.78
Volume1.97 million shs
Average Volume1.33 million shs
Market Capitalization$93.53 billion
P/E Ratio19.75
Dividend Yield1.19%
Beta1

Competitors

Anthem (NYSE:ANTM) Vs. PFE, ABT, NVS, MRK, ABBV, and TMO

Should you be buying ANTM stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Anthem, including Pfizer (PFE), Abbott Laboratories (ABT), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), and Thermo Fisher Scientific (TMO).

Anthem (NYSE:ANTM) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Profitability

This table compares Anthem and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anthem4.22%18.45%7.27%
Pfizer17.85%24.88%9.32%

Dividends

Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.2%. Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.0%. Anthem pays out 23.3% of its earnings in the form of a dividend. Pfizer pays out 52.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Anthem has raised its dividend for 1 consecutive years and Pfizer has raised its dividend for 1 consecutive years.

Institutional & Insider Ownership

89.4% of Anthem shares are owned by institutional investors. Comparatively, 67.4% of Pfizer shares are owned by institutional investors. 0.2% of Anthem shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Anthem and Pfizer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anthem031602.84
Pfizer010302.23

Anthem currently has a consensus target price of $365.60, indicating a potential downside of 4.26%. Pfizer has a consensus target price of $38.5714, indicating a potential downside of 1.17%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Anthem.

Risk & Volatility

Anthem has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Pfizer has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Valuation & Earnings

This table compares Anthem and Pfizer's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anthem$104.21 billion0.90$4.81 billion$19.4419.64
Pfizer$51.75 billion4.21$16.27 billion$2.9513.23

Pfizer has lower revenue, but higher earnings than Anthem. Pfizer is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Anthem (NYSE:ANTM) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Anthem and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anthem4.22%18.45%7.27%
Abbott Laboratories10.50%18.19%8.29%

Dividends

Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.2%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Anthem pays out 23.3% of its earnings in the form of a dividend. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Anthem has increased its dividend for 1 consecutive years and Abbott Laboratories has increased its dividend for 49 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Valuation and Earnings

This table compares Anthem and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anthem$104.21 billion0.90$4.81 billion$19.4419.64
Abbott Laboratories$31.90 billion6.66$3.69 billion$3.2437.04

Anthem has higher revenue and earnings than Abbott Laboratories. Anthem is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Anthem and Abbott Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anthem031602.84
Abbott Laboratories121302.75

Anthem currently has a consensus target price of $365.60, indicating a potential downside of 4.26%. Abbott Laboratories has a consensus target price of $124.0588, indicating a potential upside of 3.38%. Given Abbott Laboratories' higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than Anthem.

Volatility & Risk

Anthem has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Abbott Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Institutional and Insider Ownership

89.4% of Anthem shares are held by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are held by institutional investors. 0.2% of Anthem shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Anthem beats Abbott Laboratories on 9 of the 17 factors compared between the two stocks.

Novartis (NYSE:NVS) and Anthem (NYSE:ANTM) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.4%. Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.2%. Novartis pays out 39.7% of its earnings in the form of a dividend. Anthem pays out 23.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has increased its dividend for 1 consecutive years and Anthem has increased its dividend for 1 consecutive years.

Institutional and Insider Ownership

9.9% of Novartis shares are held by institutional investors. Comparatively, 89.4% of Anthem shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.2% of Anthem shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Novartis and Anthem, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novartis24602.33
Anthem031602.84

Novartis presently has a consensus price target of $108.50, indicating a potential upside of 23.53%. Anthem has a consensus price target of $365.60, indicating a potential downside of 4.26%. Given Novartis' higher possible upside, analysts clearly believe Novartis is more favorable than Anthem.

Profitability

This table compares Novartis and Anthem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novartis14.71%24.39%10.59%
Anthem4.22%18.45%7.27%

Valuation & Earnings

This table compares Novartis and Anthem's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$47.50 billion4.23$11.73 billion$5.2416.76
Anthem$104.21 billion0.90$4.81 billion$19.4419.64

Novartis has higher earnings, but lower revenue than Anthem. Novartis is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Novartis has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Anthem has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Merck & Co., Inc. (NYSE:MRK) and Anthem (NYSE:ANTM) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Insider & Institutional Ownership

72.9% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 89.4% of Anthem shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 0.2% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Merck & Co., Inc. and Anthem's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.24$9.84 billion$5.1915.14
Anthem$104.21 billion0.90$4.81 billion$19.4419.64

Merck & Co., Inc. has higher earnings, but lower revenue than Anthem. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Merck & Co., Inc. and Anthem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
Anthem4.22%18.45%7.27%

Analyst Ratings

This is a summary of recent recommendations and price targets for Merck & Co., Inc. and Anthem, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021102.85
Anthem031602.84

Merck & Co., Inc. currently has a consensus target price of $96.2727, suggesting a potential upside of 22.53%. Anthem has a consensus target price of $365.60, suggesting a potential downside of 4.26%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, equities research analysts clearly believe Merck & Co., Inc. is more favorable than Anthem.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.3%. Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.2%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Anthem pays out 23.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Anthem has increased its dividend for 1 consecutive years.

Volatility and Risk

Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Anthem has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.

Summary

Merck & Co., Inc. beats Anthem on 9 of the 16 factors compared between the two stocks.

Anthem (NYSE:ANTM) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Volatility & Risk

Anthem has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, AbbVie has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Dividends

Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.2%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.8%. Anthem pays out 23.3% of its earnings in the form of a dividend. AbbVie pays out 58.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Anthem has raised its dividend for 1 consecutive years and AbbVie has raised its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

89.4% of Anthem shares are owned by institutional investors. Comparatively, 67.5% of AbbVie shares are owned by institutional investors. 0.2% of Anthem shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Anthem and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anthem4.22%18.45%7.27%
AbbVie18.16%439.24%13.22%

Analyst Ratings

This is a breakdown of current recommendations for Anthem and AbbVie, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anthem031602.84
AbbVie121302.75

Anthem currently has a consensus price target of $365.60, suggesting a potential downside of 4.26%. AbbVie has a consensus price target of $115.75, suggesting a potential upside of 6.16%. Given AbbVie's higher possible upside, analysts clearly believe AbbVie is more favorable than Anthem.

Earnings & Valuation

This table compares Anthem and AbbVie's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anthem$104.21 billion0.90$4.81 billion$19.4419.64
AbbVie$33.27 billion5.78$7.88 billion$8.9412.20

AbbVie has lower revenue, but higher earnings than Anthem. AbbVie is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Anthem on 9 of the 17 factors compared between the two stocks.

Thermo Fisher Scientific (NYSE:TMO) and Anthem (NYSE:ANTM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Volatility & Risk

Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Anthem has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

Dividends

Thermo Fisher Scientific pays an annual dividend of $1.04 per share and has a dividend yield of 0.2%. Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.2%. Thermo Fisher Scientific pays out 8.4% of its earnings in the form of a dividend. Anthem pays out 23.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Thermo Fisher Scientific has increased its dividend for 3 consecutive years and Anthem has increased its dividend for 1 consecutive years.

Institutional & Insider Ownership

87.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 89.4% of Anthem shares are owned by institutional investors. 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 0.2% of Anthem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Thermo Fisher Scientific and Anthem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thermo Fisher Scientific17.12%21.35%10.55%
Anthem4.22%18.45%7.27%

Analyst Recommendations

This is a summary of current ratings for Thermo Fisher Scientific and Anthem, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thermo Fisher Scientific031802.86
Anthem031602.84

Thermo Fisher Scientific currently has a consensus target price of $527.05, suggesting a potential upside of 9.26%. Anthem has a consensus target price of $365.60, suggesting a potential downside of 4.26%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, equities analysts plainly believe Thermo Fisher Scientific is more favorable than Anthem.

Valuation & Earnings

This table compares Thermo Fisher Scientific and Anthem's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$25.54 billion7.42$3.70 billion$12.3539.06
Anthem$104.21 billion0.90$4.81 billion$19.4419.64

Anthem has higher revenue and earnings than Thermo Fisher Scientific. Anthem is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Thermo Fisher Scientific beats Anthem on 11 of the 17 factors compared between the two stocks.


Anthem Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Pfizer logo
PFE
Pfizer
2.3$39.03+0.3%$217.69 billion$51.75 billion25.18Analyst Revision
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$120.00+3.8%$212.58 billion$31.90 billion63.49Earnings Announcement
News Coverage
Gap Up
Novartis logo
NVS
Novartis
2.0$87.83+0.6%$201.02 billion$47.50 billion28.42Upcoming Earnings
Analyst Report
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.2$78.57+1.2%$198.81 billion$46.84 billion17.38Increase in Short Interest
AbbVie logo
ABBV
AbbVie
2.8$109.03+0.4%$192.42 billion$33.27 billion23.05Analyst Revision
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.1$482.36+1.1%$189.58 billion$25.54 billion39.54
Eli Lilly and logo
LLY
Eli Lilly and
2.1$190.61+0.5%$182.79 billion$22.32 billion31.15Upcoming Earnings
Medtronic logo
MDT
Medtronic
2.7$128.28+1.7%$172.93 billion$28.91 billion48.96
Novo Nordisk A/S logo
NVO
Novo Nordisk A/S
1.4$73.28+0.8%$172.56 billion$18.30 billion27.55
Amgen logo
AMGN
Amgen
2.3$259.14+1.2%$149.21 billion$23.36 billion20.90Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$66.08+0.7%$147.62 billion$26.15 billion-600.67Analyst Upgrade
AstraZeneca logo
AZN
AstraZeneca
2.1$52.27+1.2%$137.19 billion$24.38 billion54.45Analyst Report
Sanofi logo
SNY
Sanofi
1.5$52.00+0.3%$130.93 billion$40.00 billion22.22Decrease in Short Interest
Analyst Revision
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.1$37.70+0.7%$101.51 billion$43.10 billion11.60Analyst Report
Analyst Revision
Stryker logo
SYK
Stryker
2.0$258.43+0.7%$97.25 billion$14.88 billion56.06Upcoming Earnings
Analyst Revision
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$811.11+0.0%$96.02 billion$4.48 billion92.38News Coverage
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.38+0.6%$83.58 billion$22.45 billion68.43Analyst Report
Analyst Revision
News Coverage
Zoetis logo
ZTS
Zoetis
2.2$168.74+0.5%$80.15 billion$6.26 billion50.07Increase in Short Interest
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$256.44+1.0%$74.51 billion$17.12 billion93.93Analyst Revision
News Coverage
HCA Healthcare logo
HCA
HCA Healthcare
2.5$192.94+1.0%$65.01 billion$51.34 billion19.51Upcoming Earnings
Analyst Report
Moderna logo
MRNA
Moderna
1.6$156.78+3.3%$62.79 billion$60.21 million-96.78Analyst Report
Insider Selling
Boston Scientific logo
BSX
Boston Scientific
2.0$41.13+0.6%$58.43 billion$10.74 billion15.76
Illumina logo
ILMN
Illumina
1.6$398.39+1.5%$58.13 billion$3.54 billion92.43Upcoming Earnings
Humana logo
HUM
Humana
2.1$443.00+0.7%$57.15 billion$64.89 billion14.20
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$220.16+0.4%$56.98 billion$4.16 billion27.80Analyst Report
Analyst Revision
News Coverage
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.4$89.63+1.2%$55.75 billion$4.35 billion71.70News Coverage
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$504.42+0.9%$54.04 billion$7.86 billion18.44Analyst Report
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$16.84+0.7%$53.14 billion$30.20 billion56.14Analyst Downgrade
Align Technology logo
ALGN
Align Technology
1.9$596.20+1.3%$47.18 billion$2.41 billion27.12Analyst Revision
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$532.27+0.7%$45.58 billion$2.41 billion92.73
Baxter International logo
BAX
Baxter International
1.9$87.07+0.6%$43.98 billion$11.36 billion49.47
Biogen logo
BIIB
Biogen
1.9$273.20+1.5%$41.62 billion$14.38 billion9.04Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Centene logo
CNC
Centene
1.9$65.43+0.1%$38.05 billion$74.64 billion18.23Upcoming Earnings
BioNTech logo
BNTX
BioNTech
0.9$156.18+4.3%$37.72 billion$121.63 million-78.09Analyst Report
Gap Up
DexCom logo
DXCM
DexCom
1.9$388.91+1.1%$37.61 billion$1.48 billion160.71
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$166.54+0.6%$36.79 billion$4.99 billion38.91News Coverage
Alcon logo
ALC
Alcon
1.5$74.34+0.8%$36.29 billion$7.51 billion-50.57
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.1$173.81+0.7%$36.21 billion$7.98 billion1,086.38Analyst Revision
News Coverage
McKesson logo
MCK
McKesson
2.2$194.53+0.4%$30.96 billion$231.05 billion14.80Insider Selling
ResMed logo
RMD
ResMed
1.5$205.70+0.0%$29.93 billion$2.96 billion44.14
Teladoc Health logo
TDOC
Teladoc Health
1.7$180.91+1.8%$27.91 billion$553.31 million-126.51Increase in Short Interest
BeiGene logo
BGNE
BeiGene
1.1$292.75+3.6%$26.85 billion$428.21 million-14.49
Seagen logo
SGEN
Seagen
1.7$144.76+0.5%$26.11 billion$916.71 million56.99Increase in Short Interest
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.4$260.00+0.2%$25.39 billion$11.55 billion30.27Analyst Report
News Coverage
AmerisourceBergen logo
ABC
AmerisourceBergen
1.7$120.50+0.8%$24.67 billion$189.89 billion-7.18Analyst Revision
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$319.19+0.8%$23.57 billion$1.84 billion84.22
Genmab A/S logo
GMAB
Genmab A/S
1.4$35.74+0.4%$23.44 billion$804.57 million27.71Analyst Report
News Coverage
Cerner logo
CERN
Cerner
2.4$75.32+0.8%$22.77 billion$5.69 billion29.42
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.7$38.50+0.3%$22.55 billion$19.58 billion15.28News Coverage
Exact Sciences logo
EXAS
Exact Sciences
1.8$125.62+1.5%$21.24 billion$876.29 million-56.84Analyst Upgrade
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.